• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Bracco buys 15% stake in Esaote

Article

Italian medical imaging firms Bracco Diagnostics and Esaote Biomedicaare establishing closer ties, thanks to Bracco's purchase of a15% position in Esaote. The investment complements an R&Deffort between the firms to optimize Bracco's contrast

Italian medical imaging firms Bracco Diagnostics and Esaote Biomedicaare establishing closer ties, thanks to Bracco's purchase of a15% position in Esaote. The investment complements an R&Deffort between the firms to optimize Bracco's contrast agentswith Esaote's ultrasound scanners.

Bracco of Milan purchased the equity position in December,according to Esaote executive vice president Fabrizio Landi. Otherinvestors in Genoa-based Esaote include the vendor's management,with a 13% share of the company, and four groups of institutionalinvestors who hold the rest of shares outstanding.

Bracco's investment grew from a relationship that the companyformed with Esaote early last year for optimizing contrast agentswith imaging devices, Landi said. That collaboration sprang fromthe belief that some new contrast-based imaging techniques, suchas interventional MRI and second-harmonic ultrasound imaging,would benefit from better integration between devices and contrast.

This work will accelerate under the new investment agreement,according to Susanna Leto di Priolo, Bracco director of publicrelations.

"Bracco's acquisition in Esaote is the natural consequenceof agreements already in place concerning research on new contrastmedia for ultrasound diagnostic imaging," said Leto di Priolo."The two companies intend to intensify research in this fieldby uniting the contrast media research capability of Bracco'sGeneva laboratories with the sophisticated technology of Esaote'slaboratories."

Landi emphasized that Esaote devices will not be limited toworking with Bracco agents, and vice versa.

The investment will put Esaote on firm footing as the companylays the groundwork for an initial public offering later thisyear. Esaote plans to offer a large number of shares on the Milanstock exchange. Existing Esaote shareholders will continue tohold a majority stake in the company, Landi said.

"A solid part of our shares is now owned by industrialpartners," Landi said, which should help Esaote keep a long-termperspective as it releases stock to the public.

Recent Videos
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Teleradiology and Breast Imaging: Keys to Facilitating Personalized Service, Efficiency and Equity
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 3
Related Content
© 2025 MJH Life Sciences

All rights reserved.